123 related articles for article (PubMed ID: 31184333)
1. ASTEMIZOLE, AN INHIBITOR OF ETHER-À-GO-GO-1 POTASSIUM CHANNEL, INCREASES THE ACTIVITY OF THE TYROSINE KINASE INHIBITOR GEFITINIB IN BREAST CANCER CELLS.
García-Quiroz J; González-González ME; Díaz L; Ordaz-Rosado D; Segovia-Mendoza M; Prado-García H; Larrea F; García-Becerra R
Rev Invest Clin; 2019; 71(3):186-194. PubMed ID: 31184333
[TBL] [Abstract][Full Text] [Related]
2. Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy.
García-Quiroz J; García-Becerra R; Barrera D; Santos N; Avila E; Ordaz-Rosado D; Rivas-Suárez M; Halhali A; Rodríguez P; Gamboa-Domínguez A; Medina-Franco H; Camacho J; Larrea F; Díaz L
PLoS One; 2012; 7(9):e45063. PubMed ID: 22984610
[TBL] [Abstract][Full Text] [Related]
3. In vivo dual targeting of the oncogenic Ether-à-go-go-1 potassium channel by calcitriol and astemizole results in enhanced antineoplastic effects in breast tumors.
García-Quiroz J; García-Becerra R; Santos-Martínez N; Barrera D; Ordaz-Rosado D; Avila E; Halhali A; Villanueva O; Ibarra-Sánchez MJ; Esparza-López J; Gamboa-Domínguez A; Camacho J; Larrea F; Díaz L
BMC Cancer; 2014 Oct; 14():745. PubMed ID: 25280486
[TBL] [Abstract][Full Text] [Related]
4. Astemizole inhibits cell proliferation in human prostate tumorigenic cells expressing ether à-go-go-1 potassium channels.
Bernal-Ramos G; Hernández-Gallegos E; Vera E; Chávez-López MG; Zúñiga-García V; Sánchez-Pérez Y; Garrido E; Camacho J
Cell Mol Biol (Noisy-le-grand); 2017 Dec; 63(12):11-13. PubMed ID: 29307346
[TBL] [Abstract][Full Text] [Related]
5. Calcitriol inhibits Ether-à go-go potassium channel expression and cell proliferation in human breast cancer cells.
García-Becerra R; Díaz L; Camacho J; Barrera D; Ordaz-Rosado D; Morales A; Ortiz CS; Avila E; Bargallo E; Arrecillas M; Halhali A; Larrea F
Exp Cell Res; 2010 Feb; 316(3):433-42. PubMed ID: 19932096
[TBL] [Abstract][Full Text] [Related]
6. Astemizole-based anticancer therapy for hepatocellular carcinoma (HCC), and Eag1 channels as potential early-stage markers of HCC.
de Guadalupe Chávez-López M; Pérez-Carreón JI; Zuñiga-García V; Díaz-Chávez J; Herrera LA; Caro-Sánchez CH; Acuña-Macías I; Gariglio P; Hernández-Gallegos E; Chiliquinga AJ; Camacho J
Tumour Biol; 2015 Aug; 36(8):6149-58. PubMed ID: 25783527
[TBL] [Abstract][Full Text] [Related]
7. Eag1 Gene and Protein Expression in Human Retinoblastoma Tumors and its Regulation by pRb in HeLa Cells.
Chávez-López MG; Zúñiga-García V; Castro-Magdonel BE; Vera E; Garrido E; Sánchez-Ramos J; Ponce-Castañeda MV; Cabrera-Muñoz ML; Escobar Y; Ortiz CS; Hernández-Gallegos E; Avalos-Fuentes A; Camacho J
Genes (Basel); 2020 Jan; 11(2):. PubMed ID: 31973216
[TBL] [Abstract][Full Text] [Related]
8. Astemizole: an old anti-histamine as a new promising anti-cancer drug.
García-Quiroz J; Camacho J
Anticancer Agents Med Chem; 2011 Mar; 11(3):307-14. PubMed ID: 21443504
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative and proapoptotic effects of astemizole on cervical cancer cells.
de Guadalupe Chávez-López M; Hernández-Gallegos E; Vázquez-Sánchez AY; Gariglio P; Camacho J
Int J Gynecol Cancer; 2014 Jun; 24(5):824-8. PubMed ID: 24819656
[TBL] [Abstract][Full Text] [Related]
10. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
[TBL] [Abstract][Full Text] [Related]
11. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation.
Borowiec AS; Hague F; Harir N; Guénin S; Guerineau F; Gouilleux F; Roudbaraki M; Lassoued K; Ouadid-Ahidouch H
J Cell Physiol; 2007 Sep; 212(3):690-701. PubMed ID: 17520698
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7.
Roy J; Vantol B; Cowley EA; Blay J; Linsdell P
Oncol Rep; 2008 Jun; 19(6):1511-6. PubMed ID: 18497958
[TBL] [Abstract][Full Text] [Related]
13. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
14. [Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells].
Gong H; Yuan Y; Li Y; Zhang H; Li Y; Li W; Wang P; Shi R; Liu C; Cui L; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):255-263. PubMed ID: 31109434
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
16. The combination astemizole-gefitinib as a potential therapy for human lung cancer.
Chávez-López MG; Zúñiga-García V; Hernández-Gallegos E; Vera E; Chasiquiza-Anchatuña CA; Viteri-Yánez M; Sanchez-Ramos J; Garrido E; Camacho J
Onco Targets Ther; 2017; 10():5795-5803. PubMed ID: 29263676
[TBL] [Abstract][Full Text] [Related]
17. Estrogens and human papilloma virus oncogenes regulate human ether-à-go-go-1 potassium channel expression.
Díaz L; Ceja-Ochoa I; Restrepo-Angulo I; Larrea F; Avila-Chávez E; García-Becerra R; Borja-Cacho E; Barrera D; Ahumada E; Gariglio P; Alvarez-Rios E; Ocadiz-Delgado R; Garcia-Villa E; Hernández-Gallegos E; Camacho-Arroyo I; Morales A; Ordaz-Rosado D; García-Latorre E; Escamilla J; Sánchez-Peña LC; Saqui-Salces M; Gamboa-Dominguez A; Vera E; Uribe-Ramírez M; Murbartián J; Ortiz CS; Rivera-Guevara C; De Vizcaya-Ruiz A; Camacho J
Cancer Res; 2009 Apr; 69(8):3300-7. PubMed ID: 19351862
[TBL] [Abstract][Full Text] [Related]
18. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Irwin ME; Mueller KL; Bohin N; Ge Y; Boerner JL
J Cell Physiol; 2011 Sep; 226(9):2316-28. PubMed ID: 21660955
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
20. Tetrandrine, a novel inhibitor of ether-à-go-go-1 (Eag1), targeted to cervical cancer development.
Wang X; Chen Y; Li J; Guo S; Lin X; Zhang H; Zhan Y; An H
J Cell Physiol; 2019 May; 234(5):7161-7173. PubMed ID: 30362536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
